Global Anemia Treatment Market size is expected to be worth around USD 19.1 Billion by 2033, from USD 9.7 Billion in 2023, growing at a CAGR of 7.2% Lawrence John Prudour +91 91308 55334 ...

Chronic kidney disease may also be identified when it leads to one of its recognized complications, such as cardiovascular disease, anemia or pericarditis. There is no specific treatment ...

Anemia is highly prevalent in patients with ... human erythropoietin therapy in anemic patients with chronic kidney disease and concomitant heart disease have demonstrated a reduction in left ...

AstraZeneca is paying $160 million for FibroGen’s China business, giving the U.K.-based Big Pharma the regional rights to ...

AstraZeneca walked away from the bulk of its roxadustat partnership with FibroGen—though the pharma at the time decided to retain its relationship with the biotech’s China operations.

By selling its China business to AstraZeneca, FibroGen can focus on developing a prostate cancer drug and potentially ...

FibroGen (NASDAQ:FGEN – Get Free Report) and Roche (OTCMKTS:RHHBY – Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the ...

Modus Therapeutics Holding AB ("Modus Therapeutics") hereby publishes the year-end report for 2024. The report is available as an attached document and on the company's ...

The deal comes at a time when the Anglo-Swedish pharma company is facing a string of investigations in the country, ...

The company, now based in North Beach, has lost more than $2 billion over 29 years. Its only approved drug, called roxadustat ...

Purchase price represents enterprise value of $85 million plus FibroGen net cash held in China at closing, currently ...